References
- PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
- WilliamsRRigbyASAireyMRobinsonMFordHMultiple sclerosis: its epidemiological, genetic, and health care impactJ Epidemiol Community Health19954965635698596089
- CompstonAColesAMultiple sclerosisLancet200235993131221123111955556
- CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
- KeeganBMNoseworthyJHMultiple sclerosisAnn Rev Medic200253285302
- Koch-HenriksenNThe Danish Multiple Sclerosis Registry: a 50-year follow-upMult Scler19995429329610467392
- MayrWTPittockSJMcClellandRLJorgensenNWNoseworthyJHRodriguezMIncidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000Neurology200361101373137714638958
- HawkinsSAMcDonnellGVBenign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factorsJ Neurol Neurosurg Psychiatry199967214815210406979
- WhitacreCCReingoldSCO’LooneyPAA gender gap in autoimmunity: Task Force on Gender, Multiple Sclerosis and AutoimmunityScience199928354061277127810084932
- OrtonSMHerreraBMYeeIMSex ratio of multiple sclerosis in Canada: a longitudinal studyLancet Neurol200651193293617052660
- KisterIChamotESalterARCutterGRBaconTEHerbertJDisability in multiple sclerosis: a reference for patients and cliniciansNeurology201380111018102423427319
- SadovnickADEbersGCWilsonRWPatyDWLife expectancy in patients attending multiple sclerosis clinicsNeurology19924259919941579256
- CharcotJMHistologie de la sclerose en plaquesGaz Hop Civ Mil Empire Ottoman186841554555
- PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
- StangelMFredriksonSMeinlEPetzoldAStuveOTumaniHThe utility of cerebrospinal fluid analysis in patients with multiple sclerosisNat Rev Neurol20139526727623528543
- KuenzBDeisenhammerFBergerTReindlMDiagnostic biomarkers in multiple sclerosisExpert Opinion Medical Diagn200712225233
- KatsavosSAnagnostouliMBiomarkers in multiple sclerosis: an up-to-date overviewMult Scler Int2013201334050823401777
- LeoneMABarizzoneNEspositoFAssociation of genetic markers with CSF oligoclonal bands in multiple sclerosis patientsPloS One201386e6440823785401
- RudickRAThe elusive biomarker for personalized medicine in multiple sclerosis: the search continuesNeurology201279649849922573625
- OberwahrenbrockTSchipplingSRingelsteinMRetinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomographyMult Scler Int2012201253030522888431
- VukusicSConfavreuxCPrimary and secondary progressive multiple sclerosisJ Neurol Sci2003206215315512559503
- HagmanSRaunioMRossiMDastidarPElovaaraIDisease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up studyJ Neuroimmunol20112341–214114721397339
- FreedmanMSSelchenDArnoldDLTreatment optimization in MS: Canadian MS Working Group updated recommendationsCan J Neurol Sci201340330732323603165
- KieseierBCWiendlHHemmerBHartungHPTreatment and treatment trials in multiple sclerosisCurr Opin Neurol200720328629317495622
- SpainRICameronMHBourdetteDRecent developments in multiple sclerosis therapeuticsBMC Med200977419968863
- FilippiniGBrusaferriFSibleyWACorticosteroids or ACTH for acute exacerbations in multiple sclerosisCochrane Database Syst Rev20004CD00133111034713
- RudickRACohenJAWeinstock-GuttmanBKinkelRPRansohoffRMManagement of multiple sclerosisN Engl J Med199733722160416119371858
- BerkovichRTreatment of acute relapses in multiple sclerosisNeurotherapeutics20131019710523229226
- BurtonJMO’ConnorPWHoholMBeyeneJOral versus intravenous steroids for treatment of relapses in multiple sclerosisCochrane Database Syst Rev201212CD00692123235634
- MyhrKMMellgrenSICorticosteroids in the treatment of multiple sclerosisActa Neurologica Scand Suppl20091897380
- LassmannHPathology and disease mechanisms in different stages of multiple sclerosisJ Neurol Sci Epub622013
- BøLEsiriMEvangelouNKuhlmannTDemyelination and remyelination in multiple sclerosisDuncanIDFranklinRJMMyelin Repair and Neuroprotection in Multiple SclerosisNew YorkSpringer20132345
- CraytonHHeymanRARossmanHSA multimodal approach to managing the symptoms of multiple sclerosisNeurology20046311 Suppl 5S12S1815596731
- KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
- Weinstock-GuttmanBRansohoffRMKinkelRPRudickRAThe interferons: biological effects, mechanisms of action, and use in multiple sclerosisAnn Neurol19953717157529476
- LinLBetaseronDev Biol Stand199896971049890522
- WeberFJanovskajaJPolakTPoserSRieckmannPEffect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1bNeurology19995251069107110102432
- RudickRARansohoffRMLeeJCIn vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosisNeurology1998505129413009595977
- YongVWChabotSStuveOWilliamsGInterferon beta in the treatment of multiple sclerosis: mechanisms of actionNeurology19985136826899748010
- KieseierBCThe mechanism of action of interferon-beta in relapsing multiple sclerosisCNS Drugs201125649150221649449
- PatyDWLiDKInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study GroupNeurology19934346626678469319
- [No authors listed]Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
- JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol19963932852948602746
- FernandezOAntiquedadAArbizuTTreatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trialMult Scler19951Suppl 1S67S699345404
- PonomarenkoNADurovaOMVorobievIIAutoantibodies to myelin basic protein catalyze site-specific degradation of their antigenProc Natl Acad Sci U S A2006103228128616387849
- PonomarenkoNADurovaOMVorobievIICatalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scaleImmunol Lett20061031455016297986
- ValliASetteAKapposLBinding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patientsJ Clin Invest19939126166287679413
- OtaKMatsuiMMilfordELMackinGAWeinerHLHaflerDAT-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosisNature199034662801831871694970
- WolinskyJSCopolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disabilityNeurology1995457124512477617175
- Fridkis-HareliMTeitelbaumDGurevichEDirect binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells – specificity and promiscuityProc Natl Acad Sci U S A19949111487248767515181
- GranBTranquillLRChenMMechanisms of immunomodulation by glatiramer acetateNeurology200055111704171411113226
- BergerATh1 and Th2 responses: what are they?BMJ2000321725842410938051
- JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
- KorczynADNisipeanuPSafety profile of copolymer 1: analysis of cumulative experience in the United States and IsraelJ Neurol19962434 Suppl 1S23S268965117
- MunariLLovatiRBoikoATherapy with glatiramer acetate for multiple sclerosisCochrane Database Syst Rev20041CD00467814974077
- La MantiaLMunariLMLovatiRGlatiramer acetate for multiple sclerosisCochrane Database Syst Rev20105CD00467820464733
- YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinNPrevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrinNature1992356636463661538783
- LegerOJYednockTATannerLHumanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosisHum Antibodies1997813169265500
- KentSJKarlikSJRiceGPHornerHCA monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pigJ Magn Reson Imaging1995555355408574037
- MillerDHKhanOASheremataWAA controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med20033481152312510038
- KentSJKarlikSJCannonCA monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitisJ Neuroimmunol19955811107730443
- ElicesMJNatalizumab. Elan/BiogenCurr Opin Investig Drugs200341113541362
- BauerMBrakebuschCCoisneCBeta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunityProc Natl Acad Sci U S A200910661920192519179279
- CoisneCMaoWEngelhardtBCutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosisJ Immunol2009182105909591319414741
- SheremataWAVollmerTLStoneLAWillmer-HulmeAJKollerMA safety and pharmacokinetic study of intravenous natalizumab in patients with MSNeurology19995251072107410102433
- O’ConnorPMillerDRiesterKRelapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosisMult Scler200511556857216193895
- SheremataWAMinagarAAlexanderJSVollmerTThe role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implicationsCNS Drugs2005191190992216268663
- O’ConnorPNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisExpert Opin Biol Ther20077112313617150024
- MillerDHSoonDFernandoKTMRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSNeurology200768171390140117452584
- RudickRAMillerDHassSHealth-related quality of life in multiple sclerosis: effects of natalizumabAnn Neurol200762433534617696126
- BalcerLJGalettaSLCalabresiPANatalizumab reduces visual loss in patients with relapsing multiple sclerosisNeurology200768161299130417438220
- PhillipsJTGiovannoniGLublinFDSustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosisMult Scler201117897097921421809
- Weinstock-GuttmanBGalettaSLGiovannoniGAdditional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSJ Neurol2012259589890522008873
- CadavidDJurgensenSLeeSImpact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosisPloS One201381e5329723308186
- RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med322006354991192316510745
- Biogen IdecTysabri (natalizumab): benefit/risk update and PML risk stratification2013 Available from: http://www.slideshare.net/gavingiovannoni/natalizumanAccessed September 17, 2013
- BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med2012366201870188022591293
- PlavinaTSubramanyamMBloomgrenGUse of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosisPoster presented at: 27th Annual Meeting of the CMSC and the Fifth Cooperative Meeting of the CMSC-ACTRIMSMay 29–June 1, 2013Orlando, FL
- SchwabNSchneider-HohendorfTPosevitzVL-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNeurology2013811086587123925765
- FoleyJFNatalizumab related PML: an evolving risk stratification paradigmPoster presented at: American Academy of Neurology 2013 Annual MeetingMarch 16–23, 2013San Diego, CA
- GonsetteRENeurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicityJ Neurol Sci20082741–2485318684473
- BrosnanCFCannellaBBattistiniLRaineCSCytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen speciesNeurology1995456 Suppl 6S16S217540265
- WierinckxABrevéJMercierDSchultzbergMDrukarchBVan DamAMDetoxication enzyme inducers modify cytokine production in rat mixed glial cellsJ Neuroimmunol20051661–213214315993952
- MillerEWachowiczBMajsterekIAdvances in antioxidative therapy of multiple sclerosisCurrent medicinal chemistry Epub6252013
- BogdanCNitric oxide and the immune responseNat Immunol200121090791611577346
- NathanCShilohMUReactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogensProc Natl Acad Sci U S A200097168841884810922044
- HibbsJBJrTaintorRRVavrinZRachlinEMNitric oxide: a cytotoxic activated macrophage effector moleculeBiochem Biophys Res Commun1988157187943196352
- SmithKJKapoorRFeltsPADemyelination: the role of reactive oxygen and nitrogen speciesBrain Pathol19999169929989453
- SuKGBankerGBourdetteDForteMAxonal degeneration in multiple sclerosis: the mitochondrial hypothesisCurr Neurol Neurosci Rep20099541141719664372
- AlbrechtPBouchachiaIGoebelsNEffects of dimethyl fumarate on neuroprotection and immunomodulationJ Neuroinflammation2012916322769044
- SchillingSGoelzSLinkerRLuehderFGoldRFumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClin Exp Immunol2006145110110716792679
- VandermeerenMJanssensSBorgersMGeysenJDimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cellsBiochem Biophys Res Commun1997234119239168952
- LinkerRALeeDHRyanSFumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain2011134367869221354971
- KohenRNyskaAOxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantificationToxicol Pathol200230662065012512863
- ScannevinRHChollateSJungMYFumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathwayJ Pharmacol Exp Ther2012341127428422267202
- SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot studyEur J Neurol200613660461016796584
- WakkeeMThioHBDrug evaluation: BG-12, an immunomodulatory dimethylfumarateCurr Opinion Investig Drugs2007811955962
- KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
- GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
- FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
- HutchinsonMFoxRJMillerDHClinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM studyJournal of Neurology201326092286229623749293
- ErmisUWeisJSchulzJBPML in a patient treated with fumaric acidN Engl J Med2013368171657165823614603
- van OostenBWKillesteinJBarkhofFPolmanCHWattjesMPPML in a patient treated with dimethyl fumarate from a compounding pharmacyN Engl J Med2013368171658165923614604
- SweetserMTDawsonKTBozicCManufacturer’s response to case reports of PMLN Engl J Med2013368171659166123614605
- ZeydaMPoglitschMGeyereggerRDisruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formationArthritis Rheum20055292730273916142756
- O’ConnorPWLiDFreedmanMSA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
- WarnkeCMeyer zu HörsteGHartungHPStüveOKieseierBCReview of teriflunomide and its potential in the treatment of multiple sclerosisNeuropsychiatr Dis Treat2009533334019557143
- FoxRIHerrmannMLFrangouCGMechanism of action for leflunomide in rheumatoid arthritisClin Immunol199993319820810600330
- HerrmannMLSchleyerbachRKirschbaumBJLeflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseasesImmunopharmacology2000472–327328910878294
- OhJO’ConnorPWTeriflunomide for the treatment of multiple sclerosisSemin Neurol2013331455523709212
- Iglesias-BregnaDHanakSJiZEffects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Pharmacol Exp Ther Epub Jul26
- MerrillJEHanakSPuSFTeriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Neurol200925618910319169851
- SanofiPhase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC) Available from: http://clinicaltrials.gov/show/NCT00622700. Identifier: NCT00622700Accessed September 27, 2013
- OlssonTZhiWWHöjebergBAutoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gammaJ Clin Invest19908639819851697609
- MandalaSHajduRBergstromJAlteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonistsScience2002296556634634911923495
- YoppACRandolphGJBrombergJSLeukotrienes, sphingolipids, and leukocyte traffickingJ Immunol2003171151012816975
- O’SullivanCDevKKThe structure and function of the S1P1 receptorTrends Pharmacol Sci201334740141223763867
- XieJHNomuraNKoprakSLQuackenbushEJForrestMJRosenHSphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cellsJ Immunol200317073662367012646631
- YanagawaYMasubuchiYChibaKFTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer’s patches by FTY720-induced lymphocyte homingImmunology19989545915949893050
- YanagawaYSugaharaKKataokaHKawaguchiTMasubuchiYChibaKFTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivoJ Immunol199816011549354999605152
- ChibaKYanagawaYMasubuchiYFTY720, a novel immuno-suppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homingJ Immunol199816010503750449590253
- FujinoMFuneshimaNKitazawaYAmelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatmentJ Pharmacol Exp Ther20033051707712649354
- MironVELudwinSKDarlingtonPJFingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slicesAm J Pathol201017662682269420413685
- KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
- CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
- LindseyJWHaden-PinneriKMemonNBBujaLMSudden unexpected death on fingolimodMult Scler201218101507150822300970
- RatchfordJNCostelloKReichDSCalabresiPAVaricella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimodNeurology201279192002200423035072
- RukovetsOFDA investigates PML in patient taking Gilenya2013 Available from: http://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=240Accessed September 17, 2013
- JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol19963932852948602746
- [No authors listed]Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet19983529139149815049820297
- O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
- CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
- ComiGJefferyDKapposLPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med2012366111000100922417253
- GoldRGiovannoniGSelmajKDaclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialLancet201338198842167217523562009
- KapposLLiDCalabresiPAOcrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo- controlled, multicentre trialLancet201137898051779178722047971